![]() ![]() HIV-positive patients are eligible provided the following criteria are met: At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) for this malignancy and recovered.More than 3 years since prior chemotherapy for other malignancies. ![]() No more than 1 prior chemotherapy regimen for advanced BAC.Creatinine normal OR Creatinine clearance ≥ 60 mL/min.Aspartate aminotransferase (AST) and/or alanine aminotranferease (ALT) ≤ 2.5 times upper limit of normal.Stage IIIB disease (with pleural or pericardial effusion).Histologically or cytologically confirmed bronchoalveolar carcinoma (BAC) or adenocarcinoma of the lung with BAC features meeting 1 of the following stage criteria: Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.Īfter completion of study treatment, patients are followed every 3 months for 2 years and then every 6 months for 3 years.ĪCTUAL ACCRUAL: A total of 72 patients were accrued for this study. Patients receive cetuximab IV over 1-2 hours once on days 1, 8, 15, and 22. Determine whether the presence of polymorphisms or mutations in the EGFR gene influences response in patients treated with this drug.Correlate expression of total and phosphorylated epidermal growth factor receptor (EGFR), total and phosphorylated AKT3, and total and phosphorylated MAPKinase with response in patients treated with this drug. ![]()
0 Comments
Leave a Reply. |